Previous close | 235.96 |
Open | 236.22 |
Bid | 239.49 x 1100 |
Ask | 244.52 x 800 |
Day's range | 235.42 - 241.10 |
52-week range | 212.40 - 317.17 |
Volume | |
Avg. volume | 891,804 |
Market cap | 22.968B |
Beta (5Y monthly) | 1.04 |
PE ratio (TTM) | 8.51 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.88 (1.18%) |
Ex-dividend date | 18 May 2022 |
1y target est | N/A |
According to LabCorp (LH), this partnership is expected to broaden its comprehensive, end-to-end drug development and clinical trial programs.
Investors are optimistic about LabCorp's (LH) robust Drug Development business performance and several pandemic-related developments.
LabCorp's (LH) VirSeq SARS-CoV-2 NGS Test can detect specific SARS-CoV-2 strains to help health care providers make appropriate patient treatment decisions.